Abstract 623P
Background
Cancer ranks second globally in causes of death, accounting for 21% of all fatalities. However, many types of cancer can be cured if diagnosed and treated during early stages. We propose a liquid biopsy cancer analysis method that uses deep learning and a methylation-sensitive restriction enzyme digestion followed by sequencing method to detect and classify the most common cancers worldwide at early stages.
Methods
We developed a selective methylation sensitive restriction enzyme sequencing (MRE-Seq) method combined with a prediction model based on deep neural network (DNN) learning on data from 63,266 CpG sites to identify global hypomethylation patterns. The methylation dataset was made from 96 colon cancer samples, 95 lung cancer samples, 122 gastric cancer samples, 136 breast cancer samples, and 183 control samples. To eliminate batch bias, the ANOVA test was performed during feature selection. A DNN was adopted as a classifier, and 5-fold cross validation was performed to verify the classification performance.
Results
Across four cancer types, colorectal cancer had the highest predictive performance at 0.98, followed by breast cancer at 0.97, gastric cancer at 0.96, and lung cancer at 0.93. At 95% specificity, the sensitivity for detecting early-stage cancers varied widely, with lung cancer at 50% and breast cancer at 83%. Two different metrics were used to evaluate the model's performance. The cancer classifier (performance in detecting cancer) had a sensitivity of 95.1% and a specificity of 66.7%, indicating better performance in correctly identifying cancer samples. The cancer type classifier (performance in classifying the cancer type) utilized the precision metric to evaluate the accuracy of cancer classification. Notably, breast cancer achieved the highest precision at 95.8%, followed by lung cancer at 83.3%, gastric cancer at 79.1%, and colon cancer at 69.0%.
Conclusions
The proposed classification model based on the MRE-Seq method can reliably identify cancer and normal samples and differentiate between different cancer types using only methylation information obtained from patient's blood. This approach could be used in clinical practices to help medical experts diagnose cancer earlier and at the individual level.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract